PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of frontneurosciLink to Publisher's site
 
Front Neurosci. 2013; 7: 159.
Published online Sep 19, 2013. Prepublished online Jul 1, 2013. doi:  10.3389/fnins.2013.00159
PMCID: PMC3776940
Non-genomic mechanisms of progesterone action in the brain
Meharvan Singh,* Chang Su, and Selena Ng
Department of Pharmacology and Neuroscience, Center FOR HER, Institute for Aging and Alzheimer's Disease Research, University of North Texas Health Science Center at Fort Worth, Fort Worth, TX, USA
Edited by: John J. Peluso, University of Connecticut Health Center, USA
Reviewed by: Ikuo Kimura, Kyoto University Graduate School of Pharmaceutical Sciences, Japan; Paul S. Cooke, University of Florida, USA
*Correspondence: Meharvan Singh, Department of Pharmacology and Neuroscience, University of North Texas Health Science Center at Fort Worth, 3500 Camp Bowie Blvd., Fort Worth, TX 76107, USA e-mail: meharvan.singh/at/unthsc.edu
This article was submitted to Neuroendocrine Science, a section of the journal Frontiers in Neuroscience.
Received June 20, 2013; Accepted August 19, 2013.
Progesterone is a gonadal steroid hormone whose physiological effects extend well beyond the strict confines of reproductive function. In fact, progesterone can have important effects on a variety of tissues, including the bone, the heart and the brain. Mechanistically, progesterone has been thought to exert its effects through the progesterone receptor (PR), a member of the nuclear steroid hormone superfamily, and as such, acts through specific progesterone response elements (PRE) within the promoter region of target genes to regulate transcription of such genes. This has been often described as the “genomic” mechanism of progesterone action. However, just as progesterone has a diverse range of tissue targets, the mechanisms through which progesterone elicits its effects are equally diverse. For example, progesterone can activate alternative receptors, such as membrane-associated PRs (distinct from the classical PR), to elicit the activation of several signaling pathways that in turn, can influence cell function. Here, we review various non-nuclear (i.e., non-genomic) signaling mechanisms that progesterone can recruit to elicit its effects, focusing our discussion primarily on those signaling mechanisms by which progesterone influences cell viability in the brain.
Keywords: progesterone, non-genomic, progesterone receptor, signaling, brain
Progesterone (Pregn-4-ene-3, 20-dione, P4), the natural progestin, is a major gonadal hormone that is synthesized primarily by the ovary in the female, and the testes and adrenal cortex in the male. While progesterone levels are generally higher in the female, it is worth noting that levels of progesterone during the female follicular phase of the menstrual cycle are similar to those seen in males (Strauss and Barbieri, 2004), and thus, may have important functions in males. Although the paradigmatic role for progesterone is on reproduction function, it has also been shown to exert significant extra-reproductive actions via multiple non-genomic signaling pathways. These different functions include immunomodulation (Hughes et al., 2013), inhibition of cholesterol biosynthesis (Metherall et al., 1996), and neuroprotection (Jodhka et al., 2009).
The “classical” mechanism by which progesterone elicits its effects is via the progesterone receptor (PR), which, like the estrogen receptor (ER), has classically been described as a nuclear transcription factor, acting through specific progesterone response elements (PRE) within the promoter region of target genes to regulate transcription. Two major isoforms of the classical PR exist, PR-B, and its N-terminally truncated form, PR-A [for review, see (Conneely and Lydon, 2000)]. The latter has been shown to exert negative control of not only PR-B-mediated transcription, but that mediated by the ER and glucocorticoid receptor as well (Vegeto et al., 1993). This negative regulation of ER function by a PR may underlie, at least in part, the mechanism by which progestins functionally antagonize the effects of estrogen. For example, progesterone can inhibit estrogen's ability to increase serum levels of 1, 25, dihydroxy vitamin D (Bikle et al., 1992), whose consequence may be to antagonize estrogen's beneficial effects on the bone. Relevant to post-menopausal hormone therapy, the functional antagonism exerted by progestins on estrogen's actions also underlie the rationale for combined estrogen and progestin therapy in women with an intact uterus, as the addition of a progestin reduces the risk of uterine cancer associated with un-opposed estrogen therapy (Hirvonen, 1996). However, the relationship between progesterone and ERs may not always be antagonistic. For example, Migliaccio et al. demonstrated not only a physical interaction of the PR with the ER, but that this association was necessary for progesterone to elicit the activation of a signal transduction pathway, the mitogen activated protein kinase (MAPK) pathway, in mammary tumor cells (Migliaccio et al., 1998).
While the classical mechanism by which progesterone elicits its actions is through the regulation of gene expression, progesterone has also been shown to elicit its effects via non-genomic mechanisms such as through the activation of signal transduction pathways, which in turn may be mediated by distinct PRs, including the more recently described membrane-associated PRs. Here, we review various non-nuclear signaling mechanisms by which progesterone can elicit its effects, focusing our discussion primarily on non-nuclear mechanisms by which progesterone influences cell viability in the brain.
The classical PR-mediated cellular/physiological effects of progesterone are generally not rapidly elicited, given the time required to induce the transcription of genes and then, translate those genes into protein products. In contrast, it is now clear that progesterone can elicit rapid, non-genomic actions in various tissues including the brain through alternative mechanisms. These “non-classical” effects of progesterone can be initiated rapidly at the cell surface to activate intracellular signaling pathways, through modulation of putative cell surface receptors, ion channels, and cytoplasmic second messenger cascades. It is worth noting, however, that though these effects of progesterone are termed “non-genomic,” the rapid activation of cytoplasmic kinase signaling can result in both transcription-independent and transcription-dependent effects.
Among those rapid non-nuclear signaling pathways known to be activated by progesterone include the extracellular signal-related kinase (ERK) pathways (Migliaccio et al., 1998; Singh, 2001; Nilsen and Brinton, 2002; Boonyaratanakornkit et al., 2008; Su et al., 2012), cAMP/protein kinase A (PKA) signaling (Collado et al., 1985; Petralia and Frye, 2006), PKG signaling (Peluso, 2003), Ca2+ influx/PKC activation (Swiatek-De Lange et al., 2007), phosphatidylinositol 3-kinases (PI3 K)/Akt pathway (Singh, 2001; Zheng et al., 2012) and other signal transduction cascades. In addition, progesterone (or its metabolites) can act directly and rapidly on such neurotransmitter receptors such as the GABA-A receptor (Ishihara et al., 2013) and Sigma-1/2 receptors (Cai et al., 2008; Xu et al., 2011) to regulate cellular function.
With respect to calcium signaling, several reports suggest a functional link between progesterone and intracellular Ca2+ levels [(Ca2+)i]. For example, progesterone elicits increases in intracellular Ca2+ [(Ca2+)i] levels in Xenopus oocytes resulting in oocyte maturation (Wasserman et al., 1980). However, the cellular mediators involved in the progesterone-mediated changes in [Ca2+]i remain to be determined. What is known is that intracellular Ca2+ channels (ICCs), such as IP3Rs, have been shown to be major components of the cytosolic Ca2+ regulation machinery (Berridge et al., 2000, 2003). Furthermore, several steroid hormones activate other signaling molecules that might in turn lead to activation of ICCs. In fact, both estradiol and progesterone elicit the phosphorylation of Akt in cerebral cortical cultures (Singh, 2001), a signaling protein that has been implicated in the phosphorylation of IP3Rs in Chinese hamster ovary T-cells (Khan et al., 2006). Progesterone, through an Akt-dependent pathway, can activate IP3R type 2, leading to enhancing channel activity of IP3R type 2 (Koulen et al., 2008; Hwang et al., 2009).
The consequences of activation of these signaling pathways are numerous and include influences on neurotrophin release (Su et al., 2012), neural progenitor proliferation (Liu et al., 2009), regulation of intracellular Ca2+ levels (Cai et al., 2008), and regulation of cell viability (Nilsen and Brinton, 2002, 2003; Kaur et al., 2007; Ishihara et al., 2013), all of which can contribute to the overall health and function of the brain.
From a receptor pharmacology standpoint, the mechanism of progesterone action implicates the classical PR (e.g., PR-B or its N-terminally truncated variant, PR-A). Indeed, there are neuroprotective mechanisms of progesterone that require the classical PR. For example, our laboratory has determined that the ability of progesterone to increase the expression (mRNA and protein levels) of brain-derived neurotrophic factor (BDNF), a key mediator of progesterone's protective effects, requires the classical PR (Figure (Figure1)1) (Jodhka et al., 2009). Further, Cai and colleagues (2008) have implicated the classical/intracellular PR in the protective effects of progesterone against an experimental model (middle cerebral artery occlusion) of stroke. However, evidence also exists for alternative mechanisms of action, including that which involves integral membrane PRs. For example, the effect of progesterone has been reported in the brain of PR knock-out mice (Krebs et al., 2000), suggesting PRs other than the classical PR may mediate the effect of progesterone in the CNS. In fact, several lines of evidence now support the role of cell membrane-associated PRs in mediating the effects of progesterone on the brain (Balasubramanian et al., 2008; Liu and Arbogast, 2009; Tokmakov and Fukami, 2009; Intlekofer and Petersen, 2011). The notion that membrane PRs exist is not new, and in fact, was supported by Hans Selye's pioneer work in the 40′s that showed various steroid hormones, including progesterone, had very rapid anesthetic effects in contrast to the delayed “main” hormone actions (Selye, 1942). Four decades later, specific, displaceable binding sites for progesterone were identified in synaptosomal membrane preparations (Towle and Sze, 1983; Ke and Ramirez, 1990). Further, progesterone's is quite lipophilic, having a logP value, or octanol/water partition coefficient, of 4. This value reflects the relative solubility of a compound in an organic phase (i.e., octanol) vs. an aqueous phase (e.g., water). As such, a logP value of 4 indicates that for every molecule of progesterone that partitions into the aqueous phase, 10,000 molecules partition into the organic phase. This further supports the idea that progesterone interacts with a plasma membrane-associated receptor.
Figure 1
Figure 1
Mechanism of progesterone action in the brain. This figure provides a conceptual overview of how progesterone can elicit both genomic and non-genomic effects that impact its protective effects on the brain, and exemplifies how activation of complementary (more ...)
Two types of distinct cell surface-associated proteins unrelated to classical PRs have been identified so far: membrane PRs (mPRs) and the progesterone membrane receptor component (PGMRC). The mPRs (molecular mass of approximately 40 kDa) had thought to be comprised of three subtypes, mPR α, β, and γ, which belong to the seven-transmembrane domain adiponectin Q receptor (PAQR) family (Zhu et al., 2003a,b). Two new subtypes, mPRδ and mPRε, have also been characterized recently in human brain (Pang et al., 2013). The mPRs bind to progesterone with high affinity (Kd ~5 nM) (Zhu et al., 2003a), and mediate important physiological functions in male and female reproductive tracts, liver, neuroendocrine tissues, and the immune system as well as in breast and ovarian cancer (Sleiter et al., 2009; Pang and Thomas, 2011). Uniquely, recent experimental evidence supports mPRs as G-protein-coupled receptors, as supported by the observation that activation of the mPRα can result in recruitment/activation of pertussis-sensitive inhibitory proteins (Gi) to down-regulate membrane-bound adenylyl cyclase activity in the sea trout and in humans (Thomas et al., 2007).
Despite the fact that the classical PR and mPRs have overlapping regional expression (e.g., both are expressed in the hippocampus, cortex, hypothalamus, and cerebellum) (Brinton et al., 2008; Meffre et al., 2013), their profile of ligand specificity is not identical. For example, mPRs bind to 17α-hydroxyprogesterone and 5-dihydroprogesterone with greater affinity than to the classical PRs (Grazzini et al., 1998; Smith et al., 2008). In terms of cellular distribution, under non-injured conditions, the mPRα isoform was expressed principally by neuronal cells and not by oligodendrocytes or astrocytes. However, following traumatic brain injury (TBI) mPRα expression was observed in oligodendrocytes, astrocytes, and reactive microglia. This increase in mPR expression was proposed to mediate the anti-inflammatory effects of progesterone under conditions of injury (Meffre et al., 2013). Thus, the complement of PRs expressed in the brain may be driven by the health of the tissue.
In comparison to the mPRs, the single-transmembrane protein Pgrmc1 (molecular mass 25–28 kDa) and the closely related Pgrmc2 are thought to be a part of a multi-protein complex that binds to progesterone and other steroids, as well as pharmaceutical compounds (Thomas, 2008). Pgrmc1 was originally discovered in porcine liver and vascular smooth muscles (Falkenstein et al., 1996; Meyer et al., 1998), and later cloned in other species, including humans. Pgrmc1 has also been termed 25-Dx in rat and Hpr6 in human [for review, see (Cahill, 2007)], a result of being identified in different biological systems from multiple species. Pgrmc1 has an N-terminal transmembrane domain and a putative cytoplasmic cytochrome b5 domain ligand-binding motif. The cytoplasmic domain has target sequences for binding by SH2- and SH3-domain containing proteins as well as tyrosine kinases, implicating a potential role for Pgrmc1 as an adaptor involved in protein interactions and intracellular signal transduction. The subcellular localization of Pgrmc1 has been open to argument, since it was reported to localize in endoplasmic reticulum (Nolte et al., 2000), Golgi apparatus (Sakamoto et al., 2004) and nuclei (Beausoleil et al., 2004). However, evidence supporting the cell surface localization of Pgrmc1 includes the reports by Peluso et al., (Peluso et al., 2005) and ours (Su et al., 2012), in which biotinylated Pgrmc1 was localized to the surface (i.e., plasma membrane) of non-permeabilized cells.
Both mPRs and Pgrmc are expressed at high levels in the brain, but their functions relevant to progesterone effect in the CNS have only just started to be revealed. For example, a recent report demonstrated that allopregnanolone and other neurosteroids bound to mPRδ and decreased starvation-induced apoptosis in in hippocampal neuronal cells at low nanomolar concentrations (Pang et al., 2013). In addition, mPRα, mPRβ and Pgrmc1 have been implicated in progesterone-repressed gonadotrophin-releasing hormone release from hypothalamic neurons (Sleiter et al., 2009; Bashour and Wray, 2012). Progesterone-increased neural progenitor proliferation may also be mediated by Pgrmc1 as this effect was blocked by siRNA against Pgrmc1/2 (Liu et al., 2009). Further, a recent study by Frye, et al., revealed that progesterone-facilitated lordosis (sexual behavior) was significantly reduced by antisense oligodeoxynucleotides (AS-ODNs) against mPRβ, or AS-ODNs against both mPRβ and mPRα, when administered into the ventral tegmental area (VTA) (Frye et al., 2013). This data supports the potential role of mPRs in progesterone-facilitated lordosis of rats. The cell signaling pathways and associated downstream effects for progesterone-induced non-genomic actions are summarized in Table Table11.
Table 1
Table 1
Receptor pharmacology and signaling pathways associated with progesterone-induced non-genomic effects.
The functions of membrane-associated PRs in the CNS are not limited to neurons. In fact, work from our laboratory supports that progesterone triggers BDNF release via Pgrmc1 signaling specifically from glia (Su et al., 2012). Another report showed that mPRα expression was induced in oligodendrocytes, astrocytes and reactive microglia after TBI (Meffre et al., 2013), supporting a potential role in mediating the effects of progesterone in inflammation and water homeostasis in the injured brain.
The two receptors do not always work independently. For example, Thomas and colleagues reported that activation of mPRα and -β in human myometrium leads to transactivation of PR-B (Karteris et al., 2006), as the first evidence that cross talk between the classical PR signaling and membrane-associated PR signaling exists.
It is also worth noting that the classical PR can also mediate the effects of progesterone on signaling pathways through non-genomic/extranuclear mechanisms of progesterone. Human PR-B contains a polyproline motif in its amino-terminal domain that interacts with the SH3 domain of Src (Boonyaratanakornkit et al., 2001). Therefore, cytoplasmic PR can mediate progesterone-induced rapid activation of c-Src and downstream Ras/Raf/ERK1/2 signaling independent of its transcriptional activity. Activation of the MAPK pathway ultimately results in the phosphorylation/activation of transcription factors such as c-Fos, c-Jun and nuclear PRs to control gene transcription. For example, progesterone was shown to inhibit aortic smooth muscle cell proliferation via Src phosphorylation that in turn, results in RhoA inactivation. The involvement of the PR was supported by the fact that this effect was blocked by RU486, a PR antagonist (Hsu et al., 2011). PR also mediates progesterone's effects on breast cancer development and progression by activating the Src/ERK1/2 or PI3K/Akt pathways (Saitoh et al., 2005; Fu et al., 2008), which leads to activation of the transcription factor Elk-1 and consequent changes in gene expression (Boonyaratanakornkit et al., 2008).
In addition to the well-characterized Src pathway downstream of extranuclear PR, there is evidence supporting the activation of G-protein signaling by PR in frogs (Xenopus laevis). For example, the Xenopus PR isoform related to the mammalian PR-B localizes to the plasma membrane of oocytes, and that activation of the PR regulates Xenopus oocyte maturation via the Gβ γ activation of adenylyl cyclase (Guzman et al., 2005; Evaul et al., 2007). Interestingly, another study concluded that the Xenopus ortholog of mPRβ mediated progesterone-induced oocyte maturation via the MAPK signaling (Josefsberg Ben-Yehoshua et al., 2007). Whether there is a cross talk between the PR/Gβ γ pathway and the mPRβ/MAPK pathway in this system remains unclear.
Another mechanism by which progesterone can exert protective effects is through its metabolites, which in turn, can interact with membrane-associated receptors coupled to ion-channels, such as the GABAA receptor system [see (Deutsch et al., 1992) for review]. Such metabolites include allopregnanolone (or 3α, 5α tetrahydroprogesterone), which bind to discrete sites within the hydrophobic domain of the GABAA receptor complex, and result in the potentiation of GABA-induced chloride conductance. Indeed, allopregnanolone has been suggested to play a role in mediating the protective effects of progesterone (Djebaili et al., 2004; He et al., 2004a,b; Vitarbo et al., 2004; Ardeshiri et al., 2006; Sayeed et al., 2009). In addition to the effects of allopregnanolone on the GABAA receptor, as outlined above, allopregnanolone may also elicit its protective effects through its actions on the mitochondria (Robertson et al., 2006). For example, allopregnanolone was reported to inhibit currents associated with the opening of the mitochondrial permeability transition pore (mtPTP) (Sayeed et al., 2009), and as such, may help reduce the potential apoptotic consequences of mtPTP opening (such as cytochrome c release) during insult or injury. Moreover, allopregnanolone has also been shown to exert significant effects on neurogenesis [see (Wang et al., 2008) and references cited therein for review]. Interestingly, it has been shown that allopregnanolone may also elicit its protective effects through the regulation of BDNF [see (Nin et al., 2011) and references cited therein], although the precise mechanism by which allopregnanolone elicits BDNF [i.e., what receptor(s) allopregnanolone works through] is still unclear.
In addition to the allosteric effects described above, progesterone itself may have non-allosteric influences on the GABAA receptor. Progesterone may influence the GABAA receptor via the activation of a signal transduction pathway, which in turn, influences GABA-gated currents through phosphorylation of discrete sites within certain subunits of the GABAA receptor (Vasan et al., 2003; Bell-Horner et al., 2006). Since the regulation of the GABAA receptor has been shown to modulate cell survival, particularly in models of excitotoxicity, the regulation of the GABAA receptor by progesterone may be relevant to the protective effect of progesterone seen against kainate-induced seizure activity and subsequent cell death (Hoffman et al., 2003).
And yet another non-classical by which progesterone can elicit its effects is through its interaction with the sigma 1 (σ1) receptor (Selmin et al., 1996; Seth et al., 1998). Given the reported role of the sigma 1 receptor in neuroprotection [for review, see (Maurice et al., 2006)], this mechanism may also be relevant to progesterone's protective actions.
Collectively, reports from numerous laboratories support the critical involvement of “non-genomic” signaling in mediating progesterone's effects, including its cytoprotective effects. This highlights not only the complexity by which progesterone exerts its effects on target tissues, but also reveals insight into discrete mechanisms that may be modulated for the purpose of developing novel therapeutic strategies.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
This work was supported in part by funds from the National Institutes of Health (AG022550 and AG027956), an Investigator-Initiated Research Grant from the Alzheimer's Association, and the Texas Garvey Foundation to Meharvan Singh, and funds from the American Federation of Aging Research, and American Heart Association to Chang Su.
  • Ardeshiri A., Kelley M. H., Korner I. P., Hurn P. D., Herson P. S. (2006). Mechanism of progesterone neuroprotection of rat cerebellar Purkinje cells following oxygen-glucose deprivation. Eur. J. Neurosci. 24, 2567–2574. doi: 10.1111/j.1460-9568.2006.05142.x. [PMC free article] [PubMed] [Cross Ref]
  • Balasubramanian B., Portillo W., Reyna A., Chen J. Z., Moore A. N., Dash P. K., et al. (2008). Nonclassical mechanisms of progesterone action in the brain: II. Role of calmodulin-dependent protein kinase II in progesterone-mediated signaling in the hypothalamus of female rats. Endocrinology 149, 5518–5526. doi: 10.1210/en.2008-0713. [PubMed] [Cross Ref]
  • Bashour N. M., Wray S. (2012). Progesterone directly and rapidly inhibits GnRH neuronal activity via progesterone receptor membrane component 1. Endocrinology 153, 4457–4469. doi: 10.1210/en.2012-1122. [PubMed] [Cross Ref]
  • Beausoleil S. A., Jedrychowski M., Schwartz D., Elias J. E., Villen J., Li J., et al. (2004). Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc. Natl. Acad. Sci. U.S.A. 101, 12130–12135. doi: 10.1073/pnas.0404720101. [PubMed] [Cross Ref]
  • Bell-Horner C. L., Dohi A., Nguyen Q., Dillon G. H., Singh M. (2006). ERK/MAPK pathway regulates GABAA receptors. J. Neurobiol. 66, 1467–1474. doi: 10.1002/neu.20327. [PubMed] [Cross Ref]
  • Berridge M. J., Bootman M. D., Roderick H. L. (2003). Calcium signalling: dynamics, homeostasis and remodelling. Nat. Rev. Mol. Cell Biol. 4, 517–529. doi: 10.1038/nrm1155. [PubMed] [Cross Ref]
  • Berridge M. J., Lipp P., Bootman M. D. (2000). The versatility and universality of calcium signalling. Nat. Rev. Mol. Cell Biol. 1, 11–21. doi: 10.1038/35036035. [PubMed] [Cross Ref]
  • Bikle D. D., Halloran B. P., Harris S. T., Portale A. A. (1992). Progestin antagonism of estrogen stimulated 1,25-dihydroxyvitamin D levels. J. Clin. Endocrinol. Metab. 75, 519–523. doi: 10.1210/jc.75.2.519. [PubMed] [Cross Ref]
  • Boonyaratanakornkit V., Bi Y., Rudd M., Edwards D. P. (2008). The role and mechanism of progesterone receptor activation of extra-nuclear signaling pathways in regulating gene transcription and cell cycle progression. Steroids 73, 922–928. doi: 10.1016/j.steroids.2008.01.010. [PubMed] [Cross Ref]
  • Boonyaratanakornkit V., Scott M. P., Ribon V., Sherman L., Anderson S. M., Maller J. L., et al. (2001). Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol. Cell 8, 269–280. doi: 10.1016/S1097-2765(01)00304-5. [PubMed] [Cross Ref]
  • Brinton R. D., Thompson R. F., Foy M. R., Baudry M., Wang J., Finch C. E., et al. (2008). Progesterone receptors: form and function in brain. Front. Neuroendocrinol. 29, 313–339. doi: 10.1016/j.yfrne.2008.02.001. [PMC free article] [PubMed] [Cross Ref]
  • Cahill M. A. (2007). Progesterone receptor membrane component 1: an integrative review. J. Steroid Biochem. Mol. Biol. 105, 16–36. doi: 10.1016/j.jsbmb.2007.02.002. [PubMed] [Cross Ref]
  • Cai W., Zhu Y., Furuya K., Li Z., Sokabe M., Chen L. (2008). Two different molecular mechanisms underlying progesterone neuroprotection against ischemic brain damage. Neuropharmacology 55, 127–138. doi: 10.1016/j.neuropharm.2008.04.023. [PubMed] [Cross Ref]
  • Collado M. L., Rodriguez-Manzo G., Cruz M. L. (1985). Effect of progesterone upon adenylate cyclase activity and cAMP levels on brain areas. Pharmacol. Biochem. Behav. 23, 501–504. doi: 10.1016/0091-3057(85)90408-3. [PubMed] [Cross Ref]
  • Conneely O. M., Lydon J. P. (2000). Progesterone receptors in reproduction: functional impact of the A and B isoforms. Steroids 65, 571–577. doi: 10.1016/S0039-128X(00)00115-X. [PubMed] [Cross Ref]
  • Deutsch S. I., Mastropaolo J., Hitri A. (1992). GABA-active steroids: endogenous modulators of GABA-gated chloride ion conductance. Clin. Neuropharmacol. 15, 352–364. doi: 10.1097/00002826-199210000-00002. [PubMed] [Cross Ref]
  • Djebaili M., Hoffman S. W., Stein D. G. (2004). Allopregnanolone and progesterone decrease cell death and cognitive deficits after a contusion of the rat pre-frontal cortex. Neuroscience 123, 349–359. doi: 10.1016/j.neuroscience.2003.09.023. [PubMed] [Cross Ref]
  • Evaul K., Jamnongjit M., Bhagavath B., Hammes S. R. (2007). Testosterone and progesterone rapidly attenuate plasma membrane Gbetagamma-mediated signaling in Xenopus laevis oocytes by signaling through classical steroid receptors. Mol. Endocrinol. 21, 186–196. doi: 10.1210/me.2006-0301. [PubMed] [Cross Ref]
  • Falkenstein E., Meyer C., Eisen C., Scriba P. C., Wehling M. (1996). Full-length cDNA sequence of a progesterone membrane-binding protein from porcine vascular smooth muscle cells. Biochem. Biophys. Res. Commun. 229, 86–89. doi: 10.1006/bbrc.1996.1761. [PubMed] [Cross Ref]
  • Frye C. A., Walf A. A., Kohtz A. S., Zhu Y. (2013). Membrane progestin receptors in the midbrain ventral tegmental are required for progesterone-facilitated lordosis of rats. Horm. Behav. [Epub ahead of print]. doi: 10.1016/j.yhbeh.2013.05.012. [PubMed] [Cross Ref]
  • Fu X. D., Giretti M. S., Baldacci C., Garibaldi S., Flamini M., Sanchez A. M., et al. (2008). Extra-nuclear signaling of progesterone receptor to breast cancer cell movement and invasion through the actin cytoskeleton. PLoS ONE 3:e2790. doi: 10.1371/journal.pone.0002790. [PMC free article] [PubMed] [Cross Ref]
  • Grazzini E., Guillon G., Mouillac B., Zingg H. H. (1998). Inhibition of oxytocin receptor function by direct binding of progesterone. Nature 392, 509–512. doi: 10.1038/33176. [PubMed] [Cross Ref]
  • Guzman L., Romo X., Grandy R., Soto X., Montecino M., Hinrichs M., et al. (2005). A Gbetagamma stimulated adenylyl cyclase is involved in Xenopus laevis oocyte maturation. J. Cell. Physiol. 202, 223–229. doi: 10.1002/jcp.20102. [PubMed] [Cross Ref]
  • He J., Evans C. O., Hoffman S. W., Oyesiku N. M., Stein D. G. (2004a). Progesterone and allopregnanolone reduce inflammatory cytokines after traumatic brain injury. Exp. Neurol. 189, 404–412. doi: 10.1016/j.expneurol.2004.06.008. [PubMed] [Cross Ref]
  • He J., Hoffman S. W., Stein D. G. (2004b). Allopregnanolone, a progesterone metabolite, enhances behavioral recovery and decreases neuronal loss after traumatic brain injury. Restor. Neurol. Neurosci. 22, 19–31. [PubMed]
  • Hirvonen E. (1996). Progestins. Maturitas 23Suppl., S13–S18. doi: 10.1016/0378-5122(96)01005-5. [PubMed] [Cross Ref]
  • Hoffman G. E., Moore N., Fiskum G., Murphy A. Z. (2003). Ovarian steroid modulation of seizure severity and hippocampal cell death after kainic acid treatment. Exp. Neurol. 182, 124–134. doi: 10.1016/S0014-4886(03)00104-3. [PubMed] [Cross Ref]
  • Hsu S. P., Chen T. H., Chou Y. P., Chen L. C., Kuo C. T., Lee T. S., et al. (2011). Extra-nuclear activation of progesterone receptor in regulating arterial smooth muscle cell migration. Atherosclerosis 217, 83–89. doi: 10.1016/j.atherosclerosis.2011.02.051. [PubMed] [Cross Ref]
  • Hughes G. C., Clark E. A., Wong A. H. (2013). The intracellular progesterone receptor regulates CD4+ T cells and T cell-dependent antibody responses. J. Leukoc. Biol. 93, 369–375. doi: 10.1189/jlb.1012491. [PubMed] [Cross Ref]
  • Hwang J. Y., Duncan R. S., Madry C., Singh M., Koulen P. (2009). Progesterone potentiates calcium release through IP3 receptors by an Akt-mediated mechanism in hippocampal neurons. Cell Calcium 45, 233–242. doi: 10.1016/j.ceca.2008.10.006. [PMC free article] [PubMed] [Cross Ref]
  • Intlekofer K. A., Petersen S. L. (2011). Distribution of mRNAs encoding classical progestin receptor, progesterone membrane components 1 and 2, serpine mRNA binding protein 1, and progestin and ADIPOQ receptor family members 7 and 8 in rat forebrain. Neuroscience 172, 55–65. doi: 10.1016/j.neuroscience.2010.10.051. [PMC free article] [PubMed] [Cross Ref]
  • Ishihara Y., Kawami T., Ishida A., Yamazaki T. (2013). Allopregnanolone-mediated protective effects of progesterone on tributyltin-induced neuronal injury in rat hippocampal slices. J. Steroid Biochem. Mol. Biol. 135, 1–6. doi: 10.1016/j.jsbmb.2012.12.013. [PubMed] [Cross Ref]
  • Jodhka P. K., Kaur P., Underwood W., Lydon J. P., Singh M. (2009). The differences in neuroprotective efficacy of progesterone and medroxyprogesterone acetate correlate with their effects on brain-derived neurotrophic factor expression. Endocrinology 150, 3162–3168. doi: 10.1210/en.2008-1247. [PubMed] [Cross Ref]
  • Josefsberg Ben-Yehoshua L., Lewellyn A. L., Thomas P., Maller J. L. (2007). The role of Xenopus membrane progesterone receptor beta in mediating the effect of progesterone on oocyte maturation. Mol. Endocrinol. 21, 664–673. doi: 10.1210/me.2006-0256. [PubMed] [Cross Ref]
  • Karteris E., Zervou S., Pang Y., Dong J., Hillhouse E. W., Randeva H. S., et al. (2006). Progesterone signaling in human myometrium through two novel membrane G protein-coupled receptors: potential role in functional progesterone withdrawal at term. Mol. Endocrinol. 20, 1519–1534. doi: 10.1210/me.2005-0243. [PubMed] [Cross Ref]
  • Kaur P., Jodhka P. K., Underwood W. A., Bowles C. A., De Fiebre N. C., De Fiebre C. M., et al. (2007). Progesterone increases brain-derived neuroptrophic factor expression and protects against glutamate toxicity in a mitogen-activated protein kinase- and phosphoinositide-3 kinase-dependent manner in cerebral cortical explants. J. Neurosci. Res. 85, 2441–2449. doi: 10.1002/jnr.21370. [PMC free article] [PubMed] [Cross Ref]
  • Ke F. C., Ramirez V. D. (1990). Binding of progesterone to nerve cell membranes of rat brain using progesterone conjugated to 125I-bovine serum albumin as a ligand. J. Neurochem. 54, 467–472. doi: 10.1111/j.1471-4159.1990.tb01895.x. [PubMed] [Cross Ref]
  • Khan M. T., Wagner L., 2nd., Yule D. I., Bhanumathy C., Joseph S. K. (2006). Akt kinase phosphorylation of inositol 1,4,5-trisphosphate receptors. J. Biol. Chem. 281, 3731–3737. doi: 10.1074/jbc.M509262200. [PubMed] [Cross Ref]
  • Koulen P., Madry C., Duncan R. S., Hwang J. Y., Nixon E., McClung N., et al. (2008). Progesterone potentiates IP(3)-mediated calcium signaling through Akt/PKB. Cell. Physiol. Biochem. 21, 161–172. doi: 10.1159/000113758. [PubMed] [Cross Ref]
  • Krebs C. J., Jarvis E. D., Chan J., Lydon J. P., Ogawa S., Pfaff D. W. (2000). A membrane-associated progesterone-binding protein, 25-Dx, is regulated by progesterone in brain regions involved in female reproductive behaviors. Proc. Natl. Acad. Sci. U.S.A. 97, 12816–12821. doi: 10.1073/pnas.97.23.12816. [PubMed] [Cross Ref]
  • Liu B., Arbogast L. A. (2009). Gene expression profiles of intracellular and membrane progesterone receptor isoforms in the mediobasal hypothalamus during pro-oestrus. J. Neuroendocrinol. 21, 993–1000. doi: 10.1111/j.1365-2826.2009.01920.x. [PMC free article] [PubMed] [Cross Ref]
  • Liu L., Wang J., Zhao L., Nilsen J., McClure K., Wong K., et al. (2009). Progesterone increases rat neural progenitor cell cycle gene expression and proliferation via extracellularly regulated kinase and progesterone receptor membrane components 1 and 2. Endocrinology 150, 3186–3196. doi: 10.1210/en.2008-1447. [PubMed] [Cross Ref]
  • Maurice T., Gregoire C., Espallergues J. (2006). Neuro(active)steroids actions at the neuromodulatory sigma1 (sigma1) receptor: biochemical and physiological evidences, consequences in neuroprotection. Pharmacol. Biochem. Behav. 84, 581–597. doi: 10.1016/j.pbb.2006.07.009. [PubMed] [Cross Ref]
  • Meffre D., Labombarda F., Delespierre B., Chastre A., De Nicola A. F., Stein D. G., et al. (2013). Distribution of membrane progesterone receptor alpha in the male mouse and rat brain and its regulation after traumatic brain injury. Neuroscience 231, 111–124. doi: 10.1016/j.neuroscience.2012.11.039. [PubMed] [Cross Ref]
  • Metherall J. E., Li H., Waugh K. (1996). Role of multidrug resistance P-glycoproteins in cholesterol biosynthesis. J. Biol. Chem. 271, 2634–2640. doi: 10.1074/jbc.271.5.2634. [PubMed] [Cross Ref]
  • Meyer C., Schmid R., Schmieding K., Falkenstein E., Wehling M. (1998). Characterization of high affinity progesterone-binding membrane proteins by anti-peptide antiserum. Steroids 63, 111–116. doi: 10.1016/S0039-128X(97)00143-8. [PubMed] [Cross Ref]
  • Migliaccio A., Piccolo D., Castoria G., Di Domenico M., Bilancio A., Lombardi M., et al. (1998). Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J. 17, 2008–2018. doi: 10.1093/emboj/17.7.2008. [PubMed] [Cross Ref]
  • Nilsen J., Brinton R. D. (2002). Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology 143, 205–212. doi: 10.1210/en.143.1.205. [PubMed] [Cross Ref]
  • Nilsen J., Brinton R. D. (2003). Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc. Natl. Acad. Sci. U.S.A. 100, 10506–10511. doi: 10.1073/pnas.1334098100. [PubMed] [Cross Ref]
  • Nin M. S., Martinez L. A., Pibiri F., Nelson M., Pinna G. (2011). Neurosteroids reduce social isolation-induced behavioral deficits: a proposed link with neurosteroid-mediated upregulation of BDNF expression. Front. Endocrinol. (Lausanne) 2:73. doi: 10.3389/fendo.2011.00073. [PMC free article] [PubMed] [Cross Ref]
  • Nolte I., Jeckel D., Wieland F. T., Sohn K. (2000). Localization and topology of ratp28, a member of a novel family of putative steroid-binding proteins. Biochim. Biophys. Acta 1543, 123–130. doi: 10.1016/S0167-4838(00)00188-6. [PubMed] [Cross Ref]
  • Pang Y., Dong J., Thomas P. (2013). Characterization, neurosteroid binding and brain distribution of human membrane progesterone receptors delta and {epsilon} (mPRdelta and mPR{epsilon}) and mPRdelta involvement in neurosteroid inhibition of apoptosis. Endocrinology 154, 283–295. doi: 10.1210/en.2012-1772. [PubMed] [Cross Ref]
  • Pang Y., Thomas P. (2011). Progesterone signals through membrane progesterone receptors (mPRs) in MDA-MB-468 and mPR-transfected MDA-MB-231 breast cancer cells which lack full-length and N-terminally truncated isoforms of the nuclear progesterone receptor. Steroids 76, 921–928. doi: 10.1016/j.steroids.2011.01.008. [PMC free article] [PubMed] [Cross Ref]
  • Peluso J. J. (2003). Progesterone as a regulator of granulosa cell viability. J. Steroid Biochem. Mol. Biol. 85, 167–173. doi: 10.1016/S0960-0760(03)00192-4. [PubMed] [Cross Ref]
  • Peluso J. J., Pappalardo A., Losel R., Wehling M. (2005). Expression and function of PAIRBP1 within gonadotropin-primed immature rat ovaries: PAIRBP1 regulation of granulosa and luteal cell viability. Biol. Reprod. 73, 261–270. doi: 10.1095/biolreprod.105.041061. [PubMed] [Cross Ref]
  • Petralia S. M., Frye C. A. (2006). In the ventral tegmental area, cyclic AMP mediates the actions of progesterone at dopamine type 1 receptors for lordosis of rats and hamsters. J. Neuroendocrinol. 18, 902–914. doi: 10.1111/j.1365-2826.2006.01488.x. [PubMed] [Cross Ref]
  • Robertson C. L., Puskar A., Hoffman G. E., Murphy A. Z., Saraswati M., Fiskum G. (2006). Physiologic progesterone reduces mitochondrial dysfunction and hippocampal cell loss after traumatic brain injury in female rats. Exp. Neurol. 197, 235–243. doi: 10.1016/j.expneurol.2005.09.014. [PubMed] [Cross Ref]
  • Saitoh M., Ohmichi M., Takahashi K., Kawagoe J., Ohta T., Doshida M., et al. (2005). Medroxyprogesterone acetate induces cell proliferation through up-regulation of cyclin D1 expression via phosphatidylinositol 3-kinase/Akt/nuclear factor-kappaB cascade in human breast cancer cells. Endocrinology 146, 4917–4925. doi: 10.1210/en.2004-1535. [PubMed] [Cross Ref]
  • Sakamoto H., Ukena K., Takemori H., Okamoto M., Kawata M., Tsutsui K. (2004). Expression and localization of 25-Dx, a membrane-associated putative progesterone-binding protein, in the developing Purkinje cell. Neuroscience 126, 325–334. doi: 10.1016/j.neuroscience.2004.04.003. [PubMed] [Cross Ref]
  • Sayeed I., Parvez S., Wali B., Siemen D., Stein D. G. (2009). Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism for better neuroprotective effects of allopregnanolone over progesterone. Brain Res. 1263, 165–173. doi: 10.1016/j.brainres.2009.01.045. [PubMed] [Cross Ref]
  • Selmin O., Lucier G. W., Clark G. C., Tritscher A. M., Vanden Heuvel J. P., Gastel J. A., et al. (1996). Isolation and characterization of a novel gene induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in rat liver. Carcinogenesis 17, 2609–2615. doi: 10.1093/carcin/17.12.2609. [PubMed] [Cross Ref]
  • Selye H. (1942). Correlations between the chemical structure and the pharmacological actions of the steroids. Endocrinology 30, 437–453. doi: 10.1210/endo-30-3-437. [Cross Ref]
  • Seth P., Fei Y. J., Li H. W., Huang W., Leibach F. H., Ganapathy V. (1998). Cloning and functional characterization of a sigma receptor from rat brain. J. Neurochem. 70, 922–931. doi: 10.1046/j.1471-4159.1998.70030922.x. [PubMed] [Cross Ref]
  • Singh M. (2001). Ovarian hormones elicit phosphorylation of Akt and extracellular-signal regulated kinase in explants of the cerebral cortex. Endocrine 14, 407–415. doi: 10.1385/ENDO:14:3:407. [PubMed] [Cross Ref]
  • Sleiter N., Pang Y., Park C., Horton T. H., Dong J., Thomas P., et al. (2009). Progesterone receptor A (PRA) and PRB-independent effects of progesterone on gonadotropin-releasing hormone release. Endocrinology 150, 3833–3844. doi: 10.1210/en.2008-0774. [PubMed] [Cross Ref]
  • Smith J. L., Kupchak B. R., Garitaonandia I., Hoang L. K., Maina A. S., Regalla L. M., et al. (2008). Heterologous expression of human mPRalpha, mPRbeta and mPRgamma in yeast confirms their ability to function as membrane progesterone receptors. Steroids 73, 1160–1173. doi: 10.1016/j.steroids.2008.05.003. [PMC free article] [PubMed] [Cross Ref]
  • Strauss J., Barbieri R. (2004). Yen and Jaffe's Reproductive Endocrinology. 5th Edition Philadelphia, PA: Saunders.
  • Su C., Cunningham R. L., Rybalchenko N., Singh M. (2012). Progesterone increases the release of brain-derived neurotrophic factor from glia via progesterone receptor membrane component 1 (Pgrmc1)-dependent ERK5 signaling. Endocrinology 153, 4389–4400. doi: 10.1210/en.2011-2177. [PubMed] [Cross Ref]
  • Swiatek-De Lange M., Stampfl A., Hauck S. M., Zischka H., Gloeckner C. J., Deeg C. A., et al. (2007). Membrane-initiated effects of progesterone on calcium dependent signaling and activation of VEGF gene expression in retinal glial cells. Glia 55, 1061–1073. doi: 10.1002/glia.20523. [PubMed] [Cross Ref]
  • Thomas P. (2008). Characteristics of membrane progestin receptor alpha (mPRalpha) and progesterone membrane receptor component 1 (PGMRC1) and their roles in mediating rapid progestin actions. Front. Neuroendocrinol. 29, 292–312. doi: 10.1016/j.yfrne.2008.01.001. [PMC free article] [PubMed] [Cross Ref]
  • Thomas P., Pang Y., Dong J., Groenen P., Kelder J., De Vlieg J., et al. (2007). Steroid and G protein binding characteristics of the seatrout and human progestin membrane receptor alpha subtypes and their evolutionary origins. Endocrinology 148, 705–718. doi: 10.1210/en.2006-0974. [PubMed] [Cross Ref]
  • Tokmakov A. A., Fukami Y. (2009). [Nongenomic mechanisms of progesterone]. Tsitologiia 51, 403–416. [PubMed]
  • Towle A. C., Sze P. Y. (1983). Steroid binding to synaptic plasma membrane: differential binding of glucocorticoids and gonadal steroids. J. Steroid Biochem. 18, 135–143. doi: 10.1016/0022-4731(83)90079-1. [PubMed] [Cross Ref]
  • Vasan R., Vali M., Bell-Horner C., Kaur P., Dillon G. H., Singh M. (2003). “Regulation of the GABA-A receptor by the MAPK pathway and progesterone”, in 33rd Annual Society for Neuroscience Meeting, (New Orleans, LA: ), 472.412.
  • Vegeto E., Shahbaz M. M., Wen D. X., Goldman M. E., O'Malley B. W., McDonnell D. P. (1993). Human progesterone receptor A form is a cell- and promoter-specific repressor of human progesterone receptor B function. Mol. Endocrinol. 7, 1244–1255. doi: 10.1210/me.7.10.1244. [PubMed] [Cross Ref]
  • Vitarbo E. A., Chatzipanteli K., Kinoshita K., Truettner J. S., Alonso O. F., Dietrich W. D. (2004). Tumor necrosis factor alpha expression and protein levels after fluid percussion injury in rats: the effect of injury severity and brain temperature. Neurosurgery 55, 416–424discussion: 424–415. doi: 10.1227/01.NEU.0000130036.52521.2C. [PubMed] [Cross Ref]
  • Wang J. M., Liu L., Irwin R. W., Chen S., Brinton R. D. (2008). Regenerative potential of allopregnanolone. Brain Res. Rev. 57, 398–409. doi: 10.1016/j.brainresrev.2007.08.010. [PubMed] [Cross Ref]
  • Wasserman W. J., Pinto L. H., O'Connor C. M., Smith L. D. (1980). Progesterone induces a rapid increase in [Ca2+]in of Xenopus laevis oocytes. Proc. Natl. Acad. Sci. U.S.A. 77, 1534–1536. doi: 10.1073/pnas.77.3.1534. [PubMed] [Cross Ref]
  • Xu J., Zeng C., Chu W., Pan F., Rothfuss J. M., Zhang F., et al. (2011). Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site. Nat. Commun. 2, 380. doi: 10.1038/ncomms1386. [PMC free article] [PubMed] [Cross Ref]
  • Zheng S., Huang J., Zhou K., Xiang Q., Zhang Y., Tan Z., et al. (2012). Progesterone enhances vascular endothelial cell migration via activation of focal adhesion kinase. J. Cell. Mol. Med. 16, 296–305. doi: 10.1111/j.1582-4934.2011.01305.x. [PubMed] [Cross Ref]
  • Zhu Y., Bond J., Thomas P. (2003a). Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc. Natl. Acad. Sci. U.S.A. 100, 2237–2242. doi: 10.1073/pnas.0436133100. [PubMed] [Cross Ref]
  • Zhu Y., Rice C. D., Pang Y., Pace M., Thomas P. (2003b). Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes. Proc. Natl. Acad. Sci. U.S.A. 100, 2231–2236. doi: 10.1073/pnas.0336132100. [PubMed] [Cross Ref]
Articles from Frontiers in Neuroscience are provided here courtesy of
Frontiers Media SA